sameAs
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisAlemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MSEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsSafety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerationsPregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.Relapse of neuromyelitis optica during pregnancy--treatment options and literature review.Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition.Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsMultiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10.Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.Multiple sclerosis: Skin-induced antigen-specific immune tolerance.Dysregulated RNA-Induced Silencing Complex (RISC) Assembly within CNS Corresponds with Abnormal miRNA Expression during Autoimmune Demyelination.Brain glycolipids suppress T helper cells and inhibit autoimmune demyelination.miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40.Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and PolandInfection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studyEfficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II studyFollow-on glatiramer acetateDaclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialPreliminary studies of cytokine-induced functional effects on the visual pathways in the rabbitHyperintense basal ganglia on T1-weighted magnetic resonance images in a patient with common variable immunodeficiency associated with elevated serum manganeseThyroid hormones influence human dendritic cells' phenotype, function, and subsets distributionDiscontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activityAltered innate immune response of plasmacytoid dendritic cells in multiple sclerosisHeat shock protein 70 (Hsp70) interacts with the Notch1 intracellular domain and contributes to the activity of Notch signaling in myelin-reactive CD4 T cellsInsights into multiple sclerosis provided by non-coding RNAs: meeting summary from the symposium 'non-coding RNAs in autoimmune disorders of the central nervous system' on 5 April 2013 in Warsaw, PolandNovel emerging treatments for NMOSD
P50
Q24635370-B1C0BBC1-BA71-4A6C-B2DF-242AB059032DQ33394464-9436FEBC-66A2-4B1C-997A-3E708056E3FCQ35023350-A819BEC5-32B1-4351-987E-B0F8C413A0D9Q35115898-F478574F-FF75-41E3-BFAD-99602881CA14Q36086716-B1D60E7B-84F9-4CA0-95B6-FA924AA0A927Q36753462-B9907A7D-D35D-456A-AE87-87F946FFB8E1Q37008832-957BDFA2-6143-494B-8B30-ADCB909660DCQ37459065-8619F05D-3BAE-4FBA-A02D-0093CB05A5C8Q38332747-CD773E9F-E317-4D4D-B146-593BB13FAD79Q38402123-B1783496-E3E1-42A3-8DE3-BB0DCB137F87Q38712527-2C0282C0-1983-4856-A316-3B7374466B53Q38798705-CF2723F0-9ECC-4A59-A133-7295EBC1F3D6Q40066578-D1F886DC-AC6F-463C-82F6-FCF999C74C44Q40400262-D816D8E9-0DE7-4421-B95C-1B25A2AEDA01Q40412270-8C59B74A-2223-4304-8805-949C7C408047Q40431316-0EFECD8F-1626-4156-A804-C0F7C450D796Q41085335-E5E809DB-920F-4B88-BF0E-DC08A98991E3Q46806244-ECA92F4A-7F26-4D6E-AAE5-290DFBF2E725Q47595882-A7B103E3-9093-4FE9-B1EA-36913960E943Q47824735-943FD41A-36EB-4F6A-8B91-4CA68A0C02EDQ47849889-02FEC879-8FE5-4261-B95B-25BD1E2FB105Q48156367-1A459468-ABAE-4EBE-BB75-D4CC31204FD2Q48178994-05AD789B-3066-44AD-9F3D-6AEAAE7D7380Q48706002-CD7BEF53-2F54-457E-8B5E-37A0F484F792Q49139961-1AE9C278-627C-441B-84DD-C8CF24632387Q49197695-6F846A6D-F8CE-49D8-AC74-F17F1FD16FC5Q52391534-142FAB95-779C-4B35-9E20-D5D7C9277E31Q56900782-3DB40C3B-EDC7-4E79-98CE-0326AE830EB1Q56984212-8979F4BE-2F5C-491C-8D50-D66C39885E12Q57040164-12A68A57-9B53-4507-ADE2-989C80B343D2Q59812393-F4680C57-1B2E-4D5C-A1CA-8C4A3B751534Q62033090-FD02854F-485A-4AB1-A69C-88F5478C6B5AQ69250951-7FAA0553-6B58-4962-B062-281D175975FEQ77592472-9E685032-5F64-48F2-A7EA-33E4C0C644DCQ83054828-9F4FAB6F-E42B-488C-9B18-189E0A1FE734Q83442718-70006452-E1B8-4BE9-A717-2DC43BD95544Q84371367-5B79ABEE-A76B-44F2-98AC-5D8F51B4850EQ86394460-1A42CAD7-6596-4EB9-8D90-33C8C147CA51Q87325107-96BF9E54-BEF4-4FD2-B7A7-301A29DF5A83Q91003248-2C903F26-20CB-4C94-8C55-3D39D3F558E5
P50
description
Polish neurologist
@en
Pools lecturer
@nl
polnischer Lecturer
@de
polski lekarz, neurolog
@pl
profesor d'educación superior polacu
@ast
հետազոտող
@hy
name
Krzysztof Selmaj
@ast
Krzysztof Selmaj
@ca
Krzysztof Selmaj
@de
Krzysztof Selmaj
@en
Krzysztof Selmaj
@es
Krzysztof Selmaj
@fr
Krzysztof Selmaj
@ga
Krzysztof Selmaj
@it
Krzysztof Selmaj
@nl
Krzysztof Selmaj
@pl
type
label
Krzysztof Selmaj
@ast
Krzysztof Selmaj
@ca
Krzysztof Selmaj
@de
Krzysztof Selmaj
@en
Krzysztof Selmaj
@es
Krzysztof Selmaj
@fr
Krzysztof Selmaj
@ga
Krzysztof Selmaj
@it
Krzysztof Selmaj
@nl
Krzysztof Selmaj
@pl
prefLabel
Krzysztof Selmaj
@ast
Krzysztof Selmaj
@ca
Krzysztof Selmaj
@de
Krzysztof Selmaj
@en
Krzysztof Selmaj
@es
Krzysztof Selmaj
@fr
Krzysztof Selmaj
@ga
Krzysztof Selmaj
@it
Krzysztof Selmaj
@nl
Krzysztof Selmaj
@pl
P106
P214
P1153
7005132611
P1412
P1559
Krzysztof Selmaj
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-1213-7218
P569
1955-01-01T00:00:00Z
P735
P7859
viaf-165844533